Prospective phase-II-study evaluating postoperative radiotherapy of cervical and endometrial cancer patients using protons - the APROVE-trial

• Verfasst von: Arians, Nathalie [VerfasserIn]
• Verfasst von: Lindel, Katja [VerfasserIn]
• Verfasst von: Krisam, Johannes [VerfasserIn]
• Verfasst von: Herfarth, Klaus [VerfasserIn]
• Verfasst von: Krug, David [VerfasserIn]
• Verfasst von: Akbaba, Sati [VerfasserIn]
• Verfasst von: Oelmann-Avendano, Jan Tobias [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Titel: Prospective phase-II-study evaluating postoperative radiotherapy of cervical and endometrial cancer patients using protons - the APROVE-trial
• Verf.angabe: N. Arians, K. Lindel, J. Krisam, K. Herfarth, D. Krug, S. Akbaba, J. Oelmann-Avendano and J. Debus
• E-Jahr: 2017
• Jahr: 28 November 2017
• Fussnoten: Gesehen am 18.01.2018
• Titel Quelle: Enthalten in: Radiation oncology
• Ort Quelle: London : BioMed Central, 2006
• Jahr Quelle: 2017
• Band/Heft Quelle: 12(2017) Artikel-Nummer 188, 6 Seiten
• ISSN Quelle: 1748-717X
• DOI: doi:10.1186/s13014-017-0926-5
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cervical cancer
• Sach-SW: Endometrial cancer
• Sach-SW: Gynecologic cancer
• Sach-SW: Proton therapy
• Sach-SW: Quality of life
• Sach-SW: Toxicity
• K10plus-PPN: 1567298796
• K10plus-PPN:
  Universitätsbibliothek
• Lokale URL UB: Zum Volltext

Abstract

The prognosis for patients with cervical or endometrial cancer has improved over the last decades. Thus, reducing therapy-related toxicity and impact on quality of life have become more and more important. With the development of new radiotherapy techniques like IMRT (Intensity-modulated radiotherapy) the incidence of acute and chronic toxicities has already been reduced. Nevertheless, rates of complications requiring medical treatment range from 0.7-8% according to literature. 7.7% of patients develop severe complications after 5 years with an increasing risk for complications of 0.3%/year. Particularly, the volume of the small and large bowel receiving low doses (15 Gy) has been shown to be a predictive factor for the development of higher bowel toxicity. With the introduction of proton therapy into clinical practice, there are new opportunities for optimization of organ at risk-sparing thus possibly reducing toxicity.